Ground Breaking Ultra-Low Dose Naltrexone

In the fall of 2022, Belmar Pharmacy announced its patent-pending, 2 microgram, ultra-low dose naltrexone (ULDN).

During this informative webinar, Belmar Pharmacy’s Rachel Noonan, PharmD, discussed
● What is ULDN?
● How is it different from LDN?
● ULDN’s role in pain management
● Clinical data supporting the use of ULDN
● Applying ULDN to your practice

Ultra-low dose naltrexone can be given as an adjunctive drug for a wide range of pain conditions warranting opioid therapy, including:
● Chronic low-back pain
● Osteoarthritis
● Peripheral neuropathy
● Post-operative pain

ULDN may also provide a boost to patients with depleted endorphins. Increasing endorphin levels can improve energy, resilience, and sleep.

This webinar is intended for prescribers. If you are a prescriber and would like to watch the webinar, please fill out the form below.